OneSource Specialty Pharma Ltd secures Brazilian GMP approval for its flagship facility Unit 2

OneSource Specialty Pharma Limited today announced that its flagship Unit 2 facility in Bengaluru has been granted Good Manufacturing Practices (GMP) certification by ANVISA, the Brazilian Health Regulatory Agency, following a successful regulatory inspection held in Nov 2024.

This approval marks a significant milestone in OneSource's ongoing commitment to quality and regulatory compliance. Unit 2 is OneSource's flagship site dedicated to manufacturing high quality Biologics drug substance and finished products including Drug Device Combinations (DDC) and other injectable products.

Neeraj Sharma, CEO & Managing Director of OneSource, commented: "We are proud to add ANVISA to the growing list of global regulatory agencies that have approved our flagship facility Unit 2 for its quality, compliance, and technical excellence. This approval now enables OneSource to supply pharmaceutical products specially DDCs, including GLP-1s manufactured at this site to the Brazilian market upon our customers getting their product approvals. It is a critical milestone for our company as Brazil is one of the biggest markets opening for generic Semaglutide in 2026."

Shares of Onesource Specialty Pharma Limited was last trading in BSE at Rs. 1484.55 as compared to the previous close of Rs. 1554.85. The total number of shares traded during the day was 6867 in over 1066 trades.

The stock hit an intraday high of Rs. 1514.80 and intraday low of 1444.15. The net turnover during the day was Rs. 10189245.00.

Source : Equity Bulls

Keywords

OnesourceSpecialtyPharma INE013P01021 GMPCertification Brazil ANVISA Approval FlagshipFacility Unit2